Tablet production facility
Pharmaceutical company Boehringer Ingelheim is constructing a new tablet production facility in Ingelheim, Germany.
A ground-breaking ceremony for the facility was held in August 2018.
To be 100% financed by Boehringer Ingelheim, the plant will cost an estimated €85m ($97.2m). Upon completion in 2020, it will employ more than 75 people.
Boehringer Ingelheim will produce innovative drugs at the new facility for launch in the global market. All the contractors to be hired will be based in or around Ingelheim.
Construction of the new facility marks one of the many new investments announced by Boehringer Ingelheim in 2018 to increase its research and development (R&D) and production capabilities. The company is also developing a €230m ($266.4m) biologicals development centre (BDC) within its Biberach site in Germany.
Boehringer Ingelheim also announced plans to develop two facilities in France, including a €200m ($235m) production centre for veterinary health in July 2018 and a €65m ($80m) avian vaccines production facility in April 2018.
Boehringer Ingelheim’s new tablet production facility will be located in the town of Ingelheim, which is located in the Mainz-Bingen district of Rhineland-Palatinate.
This state was chosen due to its thriving chemical and pharmaceutical industry, which generates one of the highest turnovers in the region and is an important driver of economic growth.
Also known as Solids Launch facility, the project will develop new manufacturing techniques for tablet preparations and produce them for launch worldwide. It will enable Boehringer Ingelheim to keep the entire value chain of research, development and manufacturing within Germany.
The new production facility will be equipped with a contained production train to handle highly potent compounds. It will also feature a flexibility-driven layout, which will enable rooms and equipment to be rearranged as required in order to quickly start production by the anticipated time. Highly complex production technologies such as continuous manufacturing will be used at the facility.
The development is part of Boehringer Ingelheim’s strategy to focus on innovative and flexible technologies and processes. The company plans to move the production of older drug forms to its other facilities located worldwide.
Boehringer’s Ingelheim site is considered to be one of the largest pharmaceuticals production sites in the world. The facilities are engaged in pharmaceutical production and packaging.
In 2017, a €34m ($40m) diabetes medicines production facility was developed at the site for manufacturing novel antidiabetic agents. Following the new development, Boehringer plans to relocate production of diabetes drugs to other countries such as Mexico and Greece by 2020.
Ingelheim is also home to a packaging centre developed with an investment of €49m ($69m). The facility comprises 14 packaging lines with a production capacity of more than 250 million medicine packages a year.
In addition, the Ingelheim site houses an office building named BI5, which is one of the company’s biggest administrative offices. It is designed to conserve energy and minimise its carbon footprint.
Founded in 1885, Boehringer Ingelheim is one of the 20 biggest pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, the company is engaged in the development and manufacture of human and veterinary pharmaceuticals.
Boehringer Ingelheim manufactures a range of prescription medicines for cardiovascular, diabetes, oncology, respiratory and central nervous system (CNS) disorders, as well as consumer healthcare and animal health products.
The company operates through 181 subsidiaries and employs more than 50,000 people across all its facilities.
The Columbus Innovation District is a proposed healthcare and technology hub within the Ohio State University in the state of…
Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support…
BioNTech’s manufacturing site in Marburg, Germany, will be used for the production of its Covid-19 vaccine candidate, BNT162. Based on…